What is Pasithea Therapeutics Corp's earnings per share (EPS)?

Pasithea Therapeutics Corp (ktta) reported diluted earnings per share of $-2.91 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Pasithea Therapeutics Corp Financials

KTTA

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Pasithea Therapeutics Corp (ktta) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ktta FY2025 2026-04-22

Pasithea’s core mechanic is equity-funded cash burn, with shareholder capital rather than debt or operations sustaining the platform.

Year over year, cash jumped to $55.2M from $6.9M. That happened even with operating cash outflow of -$15.2M, because financing supplied $63.5M; liquidity was rebuilt by new capital, not by the business funding itself.

The expense mix became more corporate than developmental, with SG&A above R&D at $12.9M versus $8.0M. For a business that previously showed only tiny reported revenue, that suggests overhead scaled faster than direct program spending.

The balance sheet is lightly leveraged, with liabilities of $5.0M against assets of $60.2M. That means financial pressure comes more from replacing consumed equity capital than from servicing lenders, which fits a company still operating before self-funding.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Pasithea Therapeutics Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

100

Pasithea Therapeutics Corp carries a low D/E ratio of 0.09, meaning only $0.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 11.35, Pasithea Therapeutics Corp holds $11.35 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Pasithea Therapeutics Corp generates a -37.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -94.1% the prior year.

Piotroski F-Score Weak

3/9

Pasithea Therapeutics Corp passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.74x

For every $1 of reported earnings, Pasithea Therapeutics Corp generates $0.74 in operating cash flow (-$15.2M OCF vs -$20.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$20.8M

YoY-46.3%

Pasithea Therapeutics Corp's EBITDA was -$20.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 46.3% from the prior year.

Net Income

-$20.4M

YoY-46.9%

Pasithea Therapeutics Corp reported -$20.4M in net income in fiscal year 2025. This represents a decrease of 46.9% from the prior year.

EPS (Diluted)

$-2.91

Pasithea Therapeutics Corp earned $-2.91 per diluted share (EPS) in fiscal year 2025. This represents an increase of 77.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$55.2M

YoY+696.8%

Pasithea Therapeutics Corp held $55.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

23M

Pasithea Therapeutics Corp had 23M shares outstanding in fiscal year 2025. This represents an increase of 1556.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-37.0%

YoY+57.1pp

Pasithea Therapeutics Corp's ROE was -37.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 57.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$8.0M

YoY+10.9%

Pasithea Therapeutics Corp invested $8.0M in research and development in fiscal year 2025. This represents an increase of 10.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

KTTA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21
Revenue	N/A	N/A	N/A	$487K+3130.4%	$15K
Cost of Revenue	N/A	N/A	N/A	$113K+555.3%	$17K
Gross Profit	N/A	N/A	N/A	$373K+16971.4%	-$2K
R&D Expenses	$8.0M+10.9%	$7.2M-11.1%	$8.1M+203.9%	$2.7M	N/A
SG&A Expenses	$12.9M+82.6%	$7.1M-10.5%	$7.9M-20.6%	$9.9M+120.3%	$4.5M
Operating Income	-$20.9M-46.4%	-$14.2M+10.8%	-$16.0M-26.9%	-$12.6M-179.3%	-$4.5M
Interest Expense	N/A	N/A	N/A	$102-79.9%	$508
Income Tax	N/A	N/A	N/A	N/A	N/A
Net Income	-$20.4M-46.9%	-$13.9M+12.9%	-$16.0M-14.5%	-$13.9M-541.2%	-$2.2M
EPS (Diluted)	$-2.91	$-12.69-2921.4%	$-0.42+76.1%	$-1.76-738.1%	$-0.21

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$1.4M-36.8%	$2.1M+24.2%	$1.7M	N/A	$1.6M-32.9%	$2.4M+34.8%	$1.7M
SG&A Expenses	N/A	$1.8M+5.4%	$1.7M-14.8%	$2.0M	N/A	$1.4M-10.3%	$1.6M-30.7%	$2.3M
Operating Income	N/A	-$3.1M+18.4%	-$3.8M-3.6%	-$3.7M	N/A	-$3.0M+23.8%	-$3.9M+2.4%	-$4.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$3.0M+18.3%	-$3.7M-4.3%	-$3.6M	N/A	-$3.0M+22.4%	-$3.9M-0.1%	-$3.9M
EPS (Diluted)	N/A	$-0.41+37.9%	$-0.66+59.0%	$-1.61	N/A	$-2.87+22.6%	$-3.71-0.3%	$-3.70

KTTA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21
Total Assets	$60.2M+275.0%	$16.1M-38.5%	$26.1M-42.2%	$45.2M-15.3%	$53.3M
Current Assets	$56.5M+666.2%	$7.4M-55.9%	$16.7M-51.0%	$34.1M-36.1%	$53.3M
Cash & Equivalents	$55.2M+696.8%	$6.9M-57.6%	$16.3M-50.6%	$33.1M-37.5%	$53.0M
Inventory	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	$1.3M0.0%	$1.3M0.0%	$1.3M	N/A
Total Liabilities	$5.0M+291.6%	$1.3M-52.8%	$2.7M+1.4%	$2.7M+41.1%	$1.9M
Current Liabilities	$5.0M+344.2%	$1.1M-57.5%	$2.6M+40.3%	$1.9M+319.8%	$447K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A
Total Equity	$55.2M+273.5%	$14.8M-36.8%	$23.4M-44.9%	$42.5M-17.4%	$51.4M
Retained Earnings	-$70.0M-41.2%	-$49.6M-40.4%	-$35.3M-82.5%	-$19.4M-774.1%	-$2.2M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$60.2M+341.9%	$13.6M-19.9%	$17.0M+16.0%	$14.7M-8.8%	$16.1M-13.8%	$18.6M+5.5%	$17.7M-21.2%	$22.4M
Current Assets	$56.5M+921.1%	$5.5M-36.0%	$8.6M+41.0%	$6.1M-16.9%	$7.4M-24.6%	$9.8M+13.1%	$8.6M-34.5%	$13.2M
Cash & Equivalents	$55.2M+1237.9%	$4.1M-42.9%	$7.2M+35.1%	$5.3M-22.8%	$6.9M-26.0%	$9.4M+17.5%	$8.0M-33.7%	$12.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	$1.3M0.0%	$1.3M0.0%	$1.3M0.0%	$1.3M0.0%	$1.3M0.0%	$1.3M0.0%	$1.3M
Total Liabilities	$5.0M+252.6%	$1.4M-22.2%	$1.8M+9.0%	$1.7M+31.1%	$1.3M+55.6%	$824K-44.6%	$1.5M-41.1%	$2.5M
Current Liabilities	$5.0M+261.2%	$1.4M-20.7%	$1.7M+8.9%	$1.6M+42.4%	$1.1M+69.6%	$660K-52.7%	$1.4M-43.5%	$2.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$55.2M+352.4%	$12.2M-19.6%	$15.2M+16.9%	$13.0M-12.2%	$14.8M-17.0%	$17.8M+10.1%	$16.2M-18.6%	$19.9M
Retained Earnings	-$70.0M-16.9%	-$59.9M-5.3%	-$56.9M-7.0%	-$53.1M-7.2%	-$49.6M-6.8%	-$46.4M-7.8%	-$43.0M-9.9%	-$39.2M

KTTA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	-$15.2M-9.3%	-$13.9M-8.7%	-$12.8M+12.0%	-$14.6M-358.8%	-$3.2M
Capital Expenditures	N/A	N/A	$34K-68.0%	$107K+398.1%	$22K
Free Cash Flow	N/A	N/A	-$12.8M+12.4%	-$14.7M-359.0%	-$3.2M
Investing Cash Flow	$11K	N/A	N/A	-$2.1M-9487.2%	-$22K
Financing Cash Flow	$63.5M+1306.0%	$4.5M	N/A	-$3.2M-105.7%	$55.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$3.7M	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$5.4M-86.7%	-$2.9M+25.3%	-$3.9M-26.6%	-$3.1M-25.1%	-$2.4M+21.7%	-$3.1M+22.7%	-$4.0M+6.5%	-$4.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$56.4M+48678.6%	-$116K-102.0%	$5.7M+289.3%	$1.5M+6360.3%	-$24K	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

KTTA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21
Gross Margin	N/A	N/A	N/A	76.7%+91.4pp	-14.7%
Operating Margin	N/A	N/A	N/A	-2587.3%+27338.4pp	-29925.7%
Net Margin	N/A	N/A	N/A	-2864.3%+11566.2pp	-14430.5%
Return on Equity	-37.0%+57.1pp	-94.1%-25.8pp	-68.2%-35.4pp	-32.8%-28.6pp	-4.2%
Return on Assets	-33.9%+52.6pp	-86.6%-25.4pp	-61.1%-30.3pp	-30.9%-26.8pp	-4.1%
Current Ratio	11.35+4.8	6.58+0.2	6.34-11.8	18.15-101.0	119.17
Debt-to-Equity	0.090.0	0.09-0.0	0.12+0.1	0.06+0.0	0.04
FCF Margin	N/A	N/A	N/A	-3014.8%+18201.2pp	-21216.1%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-24.9%-0.4pp	-24.5%+3.0pp	-27.5%	N/A	-16.8%+7.1pp	-23.9%-4.5pp	-19.4%
Return on Assets	N/A	-22.3%-0.4pp	-21.9%+2.5pp	-24.3%	N/A	-16.1%+5.8pp	-21.9%-4.7pp	-17.2%
Current Ratio	11.35+7.3	4.02-1.0	4.97+1.1	3.84-2.7	6.58-8.2	14.81+8.6	6.20+0.8	5.35
Debt-to-Equity	0.09-0.0	0.120.0	0.120.0	0.13+0.0	0.09+0.0	0.05-0.0	0.09-0.0	0.13
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

60 degrees pharmaceuticals, Inc. SXTP

$4.2M

Titan Pharmaceut TTNP

$6.1M

Palisade Bio Inc PALI

$326.9M

Aditxt Inc ADTX

$198K

TNF Pharmaceuticals TNFA

$9.6M

Frequently Asked Questions

Is Pasithea Therapeutics Corp profitable?

No, Pasithea Therapeutics Corp (ktta) reported a net income of -$20.4M in fiscal year 2025.

What is Pasithea Therapeutics Corp's EBITDA?

Pasithea Therapeutics Corp (ktta) had EBITDA of -$20.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Pasithea Therapeutics Corp's return on equity (ROE)?

Pasithea Therapeutics Corp (ktta) has a return on equity of -37.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Pasithea Therapeutics Corp's operating cash flow?

Pasithea Therapeutics Corp (ktta) generated -$15.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Pasithea Therapeutics Corp's total assets?

Pasithea Therapeutics Corp (ktta) had $60.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Pasithea Therapeutics Corp spend on research and development?

Pasithea Therapeutics Corp (ktta) invested $8.0M in research and development during fiscal year 2025.

How many shares does Pasithea Therapeutics Corp have outstanding?

Pasithea Therapeutics Corp (ktta) had 23M shares outstanding as of fiscal year 2025.

What is Pasithea Therapeutics Corp's current ratio?

Pasithea Therapeutics Corp (ktta) had a current ratio of 11.35 as of fiscal year 2025, which is generally considered healthy.

What is Pasithea Therapeutics Corp's debt-to-equity ratio?

Pasithea Therapeutics Corp (ktta) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Pasithea Therapeutics Corp's return on assets (ROA)?

Pasithea Therapeutics Corp (ktta) had a return on assets of -33.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Pasithea Therapeutics Corp's cash runway?

Based on fiscal year 2025 data, Pasithea Therapeutics Corp (ktta) had $55.2M in cash against an annual operating cash burn of $15.2M. This gives an estimated cash runway of approximately 44 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Pasithea Therapeutics Corp's Piotroski F-Score?

Pasithea Therapeutics Corp (ktta) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Pasithea Therapeutics Corp's earnings high quality?

Pasithea Therapeutics Corp (ktta) has an earnings quality ratio of 0.74x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Pasithea Therapeutics Corp?

Pasithea Therapeutics Corp (ktta) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.